Michelle M A Kip1,2, Sytze de Roock2,3,4, Gillian Currie2,5,6,7, Deborah A Marshall2,5,7,8, Luiza R Grazziotin2,5, Marinka Twilt2,7,9, Rae S M Yeung2,10, Susanne M Benseler2,7,9, Maud A Schreijer1, Sebastiaan J Vastert2,3,4,11, Nico Wulffraat2,3,4,11, Annet van Royen-Kerkhof2,3,4,11, Joost F Swart2,3,4,11, Maarten J IJzerman1,2,12. 1. Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands. 2. UCAN CAN-DU network (Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Diseases). 3. Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands. 4. Faculty of Medicine, Utrecht University, Utrecht, The Netherlands. 5. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 6. Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 7. Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada. 8. Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 9. Division of Rheumatology, Department of Pediatrics, Alberta Children's Hospital, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 10. Division of Rheumatology, the Hospital for Sick Children, Department of Paediatrics, Immunology and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. 11. European Reference Network RITA (Rare Immunodeficiency Autoinflammatory and Autoimmune Diseases Network). 12. University of Melbourne, Melbourne School of Population and Global Health, Parkville, Melbourne, Australia.
Abstract
Background: This study aims to quantify medication costs in juvenile idiopathic arthritis (JIA), based on subtype.Research design and methods: This study is a single-center, retrospective analysis of prospective data from electronic medical records of JIA patients, aged 0-18 years between 1 April 2011 and 31 March 2019. Patient characteristics (age, gender, subtype) and medication use were extracted. Medication use and costs were reported as: 1) mean total annual costs; 2) between-patient heterogeneity in these costs; 3) duration of medication use; and, 4) costs over the treatment course. Results: The analysis included 691 patients. Mean total medication costs were €2,103/patient/year, including €1,930/patient/year (91.8%) spent on biologicals. Costs varied considerably between subtypes, with polyarticular rheumatoid-factor positive and systemic JIA patients having the highest mean costs (€5,020/patient/year and €4,790/patient/year, respectively). Mean annual medication costs over the patient's treatment course ranged from <€1,000/year (71.1% of patients) to >€11,000/year (2.5% of patients). Etanercept and adalimumab were the most commonly used biologicals. Cost fluctuations over the treatment course were primarily attributable to biological use.Conclusions: Polyarticular rheumatoid-factor positive and systemic JIA patients had the highest mean total annual medication costs, primarily attributable to biologicals. Costs varied considerably between subtypes, individuals, and over the treatment course.
Background: This study aims to quantify medication costs in juvenile idiopathic arthritis (JIA), based on subtype.Research design and methods: This study is a single-center, retrospective analysis of prospective data from electronic medical records of JIA patients, aged 0-18 years between 1 April 2011 and 31 March 2019. Patient characteristics (age, gender, subtype) and medication use were extracted. Medication use and costs were reported as: 1) mean total annual costs; 2) between-patient heterogeneity in these costs; 3) duration of medication use; and, 4) costs over the treatment course. Results: The analysis included 691 patients. Mean total medication costs were €2,103/patient/year, including €1,930/patient/year (91.8%) spent on biologicals. Costs varied considerably between subtypes, with polyarticular rheumatoid-factor positive and systemic JIA patients having the highest mean costs (€5,020/patient/year and €4,790/patient/year, respectively). Mean annual medication costs over the patient's treatment course ranged from <€1,000/year (71.1% of patients) to >€11,000/year (2.5% of patients). Etanercept and adalimumab were the most commonly used biologicals. Cost fluctuations over the treatment course were primarily attributable to biological use.Conclusions: Polyarticular rheumatoid-factor positive and systemic JIA patients had the highest mean total annual medication costs, primarily attributable to biologicals. Costs varied considerably between subtypes, individuals, and over the treatment course.
Entities:
Keywords:
Health care costs; health resources; juvenile idiopathic arthritis; treatment costs
Authors: Fernando García-Rodríguez; Augusto Gamboa-Alonso; Sol Jiménez-Hernández; Lucero Ochoa-Alderete; Valeria Alejandra Barrientos-Martínez; Neri Alejandro Alvarez-Villalobos; Gabriela Andrea Luna-Ruíz; Ingris Peláez-Ballestas; Ana Victoria Villarreal-Treviño; Manuel Enrique de la O-Cavazos; Nadina Rubio-Pérez Journal: Pediatr Rheumatol Online J Date: 2021-10-09 Impact factor: 3.054
Authors: Luiza R Grazziotin; Gillian Currie; Marinka Twilt; Maarten J Ijzerman; Michelle M A Kip; Hendrik Koffijberg; Susanne M Benseler; Joost F Swart; Sebastiaan J Vastert; Nico M Wulffraat; Rae S M Yeung; Deborah A Marshall Journal: Pediatr Rheumatol Online J Date: 2022-04-11 Impact factor: 3.054